NEMAURA MEDICAL INC (NMRD) Stock Fundamental Analysis
NASDAQ:NMRD - Nasdaq - US6404422080 - Common Stock - Currency: USD
Taking everything into account, NMRD scores 1 out of 10 in our fundamental rating. NMRD was compared to 190 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of NMRD have multiple concerns. NMRD has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
NMRD had negative earnings in the past year.
NMRD had a negative operating cash flow in the past year.
In the past 5 years NMRD always reported negative net income.
In the past 5 years NMRD always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -114.35%, NMRD is doing worse than 86.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.35% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-59.24%
ROA(5y)-122.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
NMRD does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
NMRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, NMRD has more shares outstanding
NMRD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for NMRD is higher compared to a year ago.
2.2 Solvency
NMRD has an Altman-Z score of -12.89. This is a bad value and indicates that NMRD is not financially healthy and even has some risk of bankruptcy.
NMRD's Altman-Z score of -12.89 is on the low side compared to the rest of the industry. NMRD is outperformed by 83.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -12.89 |
ROIC/WACCN/A
WACC5.51%
2.3 Liquidity
NMRD has a Current Ratio of 0.38. This is a bad value and indicates that NMRD is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Current ratio value of 0.38, NMRD is not doing good in the industry: 96.50% of the companies in the same industry are doing better.
NMRD has a Quick Ratio of 0.38. This is a bad value and indicates that NMRD is not financially healthy enough and could expect problems in meeting its short term obligations.
NMRD has a worse Quick ratio (0.24) than 97.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.24 |
3. Growth
3.1 Past
NMRD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.06%, which is quite impressive.
The Revenue for NMRD has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)39.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
3.2 Future
NMRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.37% yearly.
Based on estimates for the next years, NMRD will show a very strong growth in Revenue. The Revenue will grow by 238.97% on average per year.
EPS Next Y42.95%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year43.63%
Revenue Next 2Y238.97%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
NMRD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NMRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as NMRD's earnings are expected to grow with 17.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.37%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for NMRD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
0.1053
-0.02 (-17.8%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners0.14%
Inst Owner Change0%
Ins Owners120.13%
Ins Owner Change0%
Market Cap3.04M
Analysts82.86
Price Target8.67 (8133.62%)
Short Float %0%
Short Ratio0
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48.31%
Min EPS beat(2)41.18%
Max EPS beat(2)55.44%
EPS beat(4)3
Avg EPS beat(4)37.05%
Min EPS beat(4)-10.29%
Max EPS beat(4)61.87%
EPS beat(8)5
Avg EPS beat(8)17.43%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)-68.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)54.55%
EPS NQ rev (1m)0%
EPS NQ rev (3m)9.09%
EPS NY rev (1m)0%
EPS NY rev (3m)18.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-33.33%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-44.83%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.39
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-0.34
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0
BVpS-0.55
TBVpS-0.56
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -114.35% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-59.24%
ROA(5y)-122.44%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 46% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.38 | ||
| Quick Ratio | 0.24 | ||
| Altman-Z | -12.89 |
F-Score1
WACC5.51%
ROIC/WACCN/A
Cap/Depr(3y)460.04%
Cap/Depr(5y)413.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%70.59%
EPS Next Y42.95%
EPS Next 2Y17.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year43.63%
Revenue Next 2Y238.97%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-23.74%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.69%
OCF growth 3YN/A
OCF growth 5YN/A